Zoster Ups Stroke Risk in Patients With Autoimmune Disease

Share this content:
Zoster Ups Stroke Risk in Patients With Autoimmune Disease
Zoster Ups Stroke Risk in Patients With Autoimmune Disease

FRIDAY, Feb. 3, 2017 (HealthDay News) -- For patients with autoimmune diseases, the risk of stroke is increased in the few months subsequent to incident herpes zoster (HZ), according to a study published online Jan. 28 in Arthritis & Rheumatology.

Leonard H. Calabrese, D.O., from the Cleveland Clinic, and colleagues identified patients with autoimmune disease using Medicare data from Jan. 1, 2006, through Dec. 31, 2013. The authors examined whether the incidence of hospitalized stroke was increased immediately following HZ compared with incidence at later time points.

The researchers found that the crude incidence of stroke varied from 2.30 per 100 patient-years (95 percent confidence interval [CI], 0.96 to 5.52) within 90 days of HZ in patients who had HZ-related cranial nerve complications and did not receive treatment, to 0.87 per 100 patient-years (95 percent CI, 0.75 to 1.02) at 366 to 730 days for those who did not have complications and who received treatment. The overall incidence rate ratio (IRR) was 1.36 (95 percent CI, 1.10 to 1.68) for stroke in the first 90 days versus at 366 to 730 days after HZ, after multivariable adjustment for multiple stroke-related factors. Patients with zoster and cranial nerve complications had greater risk (IRR, 2.08; 95 percent CI, 0.99 to 4.36). The incidence of subsequent stroke was lower with prompt antiviral therapy (IRR, 0.83; 95 percent CI, 0.70 to 0.98).

"These data underscore the urgency of developing strategies for reducing the risk of varicella-zoster virus," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »